Compare TDOC & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDOC | NEO |
|---|---|---|
| Founded | 2002 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2015 | 2008 |
| Metric | TDOC | NEO |
|---|---|---|
| Price | $6.61 | $8.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 8 |
| Target Price | $7.56 | ★ $13.38 |
| AVG Volume (30 Days) | ★ 5.3M | 2.2M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,406,840,000.00 | N/A |
| Revenue This Year | $1.19 | $10.63 |
| Revenue Next Year | $1.25 | $9.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.41 | N/A |
| 52 Week Low | $4.40 | $4.72 |
| 52 Week High | $9.77 | $13.74 |
| Indicator | TDOC | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 58.62 | 46.32 |
| Support Level | $5.08 | $7.50 |
| Resistance Level | $7.95 | $8.84 |
| Average True Range (ATR) | 0.38 | 0.57 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 63.66 | 10.21 |
Teladoc Health Inc is engaged in the provision of virtual healthcare services, connecting patients, providers, and healthcare systems through technology-enabled platforms. The company has two reportable segments: Integrated Care and BetterHelp. The Integrated Care segment provides virtual healthcare solutions, including primary care, mental health, chronic care management, and telehealth enablement services for employers, insurers, and healthcare systems, mainly on a business-to-business basis, while the BetterHelp segment offers direct-to-consumer online mental health services, including counseling and therapy delivered through digital platforms. It generates the majority of its revenue from the Integrated Care segment.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.